
Loss of exclusivity on brands such as the antipsychotic Seroquel IR helped put a $500 million dent in AstraZeneca’s performance …
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care

